HealthDay News — A model may predict death or illicit drug overdose within 30 days of a before medically advised (BMA) discharge, according to a study published online Nov. 11 in CMAJ, the journal of ...

Of US deaths between 1999 and 2024, 0.1% had temperature exposure recorded as an underlying or contributing cause of death.

In mainland China, the declining age in gout onset between 2003 and 2022 coincided with greater disease severity and metabolic comorbidities.

Higher odds of hypertension were seen among postmenopausal US women with trouble sleeping or obstructive sleep apnea.

Increased UPF consumption was associated with higher odds of having prediabetes and impaired glucose tolerance.

Elevated Ca×P levels were associated with increased odds of developing hyperuricemia among adults in the US, especially those with overweight or obesity.

Screening for heterozygous familial hypercholesterolemia during childhood and early adulthood was not found to be cost-effective.

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

Most countries involved in FDA drug-approval trials do not receive timely market authorization for the studied drugs.

Premature mortality increased among adults in the US between 2012 and 2022, particularly among Black individuals.

A large percentage of US adults report feelings of loneliness and isolation, with societal division intensifying these feelings.

Fibromyalgia severity scores showed modest seasonal variations, with higher widespread pain reported during autumn vs summer.